Thrombin-activated Human Platelets Release two NAP-2 Variants that Stimulate Polymorphonuclear Leukocytes

Summary

Thrombin-activated human platelets release substance(s) of a prote-ic nature which induce an increase in the intracellular calcium concentration in polymorphonuclear leukocytes (PMN). Aim of this study was to characterize the platelet released product(s) responsible for PMN stimulation.

PMN-stimulating activity was isolated from platelet supernatant by FPLC and HPLC. The N-terminal sequence analysis revealed that the purified fractions consisted in 90% of a peptide of 73 amino acids and in 10% of a peptide of 74 amino acids; both are truncated forms of the connective tissue-activating peptide III (CTAP-III), a platelet a-granule product, and have 3 and 4 additional amino acids at the N-terminus compared with the neutrophil-activating peptide 2 (NAP-2): Asp-Leu-Tyr and Ser-Asp-Leu-Tyr, respectively. Treatment of platelet supernatant (previously depleted of PMN-activating nucleotides) with Affi-gel heparin resulted in the disappearance of PMN-stimulating effects, suggesting that NAP-2 variants, which are heparin-binding proteins, account for ATP-independent PMN-stimulating activity of the supernatant. Cross-desensitization between rNAP-2 and the platelet supernatant and inhibition by the anti-NAP-2 antibody are in agreement with this conclusion. Although NAP-2 and its variants are reportedly generated from the inactive precursors, CTAP-III and platelet basic protein, through a proteolytic cleavage, NAP-2 variants were not generated in our system by proteases deriving from platelets or contaminating leukocytes. Indeed, treatment of intact platelet suspensions with different protease inhibitors failed to modify the calcium stimulating activity of the resulting supernatants. In conclusion, thrombin-activated platelets release NAP-2 variants which are not generated outside the platelets by proteolytic processing but are released in an active form. This finding enhances our understanding of platelet-PMN interaction in thrombosis and inflammation.

• References

• 1 Henson PM. Interactions between neutrophils and platelets. Lab Invest 1990; 62: 391-393
• 2 Faint RW. Platelet-neutrophil interactions: their significance. Blood Rev 1992; 6: 83-91
• 3 Cerletti C, Evangelista V, Molino M, Piccardoni P, Maugeri N, de Gaetano G. Polymorphonuclear leukocytes modulate platelet function. In: The role of platelets in blood-biomaterial interactions Missirlis YF, Wautier J-L. eds. Kluwer Academic Publishers; Dordrecht: 1993: 95-106
• 4 Cerletti C, Evangelista V, Molino M, de Gaetano G. Platelet activation by polymorphonuclear leukocyte: role of cathepsin G and P-selectin. Thromb Haemost 1995; 74: 213-217
• 5 Burgers JA, Schweizer RC, Koenderman L, Bruijnzeel PLB, Akkerman JWN. Human platelets secrete chemotactic activity for eosinophils. Blood 1993; 81: 49-55
• 6 Takahashi A, Yamamoto K, Okuma M, Sasada M. Transient calcium elevation in polymorphonuclear leukocytes triggered by thrombin-activated platelets. Eur J Haematol 1992; 48: 196-201
• 7 Ward PA, Cunningham TW, McCulloch KK, Phan SH, Powell J, Johnson KJ. Platelet enhancement of O₂- responses in stimulated human neutrophils. Identification of platelet factor as adenine nucleotide. Lab Invest 1988; 58: 37-47
• 8 Del Maschio A, Dejana E, Bazzoni G. Bidirectional modulation of platelet and polymorphonuclear leukocyte activities. Ann Hematol 1993; 67: 23-31
• 9 Del Maschio A, Corvazier E, Maillet F, Kazatchkine MD, Maclouf J. Platelet-dependent induction and amplification of polymorphonuclear leucocyte lysosomal enzyme release. Br J Haematol 1989; 72: 329-335
• 10 Walz A, Dewald B, Baggiolini M. Formation and biological activity of NAP-2, a neutrophil-activating peptide derived from platelet alpha-granule precursors. In: Molecular and cellular biology of cytokines Oppenheim JJ, Powanda MC, Kluger MJ, Dinarello CA. eds. Wiley-Liss, New York: 1990: 363-368
• 11 Car BD, Baggiolini M, Walz A. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem J 1991; 275: 581-584
• 12 Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12 (1,2) 17-46
• 13 Walz A, Dewald B, von Tschamer V, Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III, and platelet factor 4 on human neutrophils. J Exp Med 1989; 170: 1745-1750
• 14 Walz A, Baggiolini M. A novel cleavage product of β-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun 1989; 159: 969-975
• 15 Cohen AB, Stevens MD, Miller EJ, Atkinson MAL, Mullenbach G. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets. Am J Physiol 1992; 263: L249-L256
• 16 Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW. Use of T7 RNA polymerase to direct expression of cloned genes. Meth Enzymol 1990; 185: 60-89
• 17 Lindley I, Aschauer H, Seifert J-M, Lam C, Brunowsky W, Kownatzki E, Thelen M, Peveri P, Dewald B, von Tscharner V, Walz A, Baggiolini M. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA 1988; 85: 9199-9203
• 18 Maugeri N, Evangelista V, Celardo A, Dell’Elba G, Martelli N, Piccardoni P, de Gaetano G, Cerletti C. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B₂ and leukotriene C₄ cooperative synthesis. Thromb Haemost 1994; 72: 450-456
• 19 Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. J Clin Invest 1986; 78: 130-137
• 20 Kuhns DB, Wright DG, Nath J, Kaplan SS, Basford RE. ATP induces transient elevations of [Ca²⁺]_i in human neutrophils and primes these cells for enhanced O₂- generation. Lab Invest 1988; 58: 448-453
• 21 Kuroki M, Takeshige K, Minakami S. ATP-induced calcium mobilization in human neutrophils. Biochim Biophys Acta 1989; 1012: 103-106
• 22 Moser B, Schumacher C, von Tscharner V, Clark-Lewis I, Baggiolini M. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991; 266: 10666-10671
• 23 Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiarowski S, Poncz M. Structural requirements of platelet chemokines for neutrophil activation. Blood 1994; 84: 2329-2339
• 24 Holt JC, Harris ME, Holt AM, Lange E, Henschen A, Niewiarowski S. Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and β-thromboglobulin. Biochemistry 1986; 25: 1988-1996
• 25 Brandt E, Van Damme J, Flad H-D. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokines 1991; 3: 311-321
• 26 Holt JC, Niewiarowski S. Conversion of low-affinity platelet factor 4 to p-thromboglobulin by plasmin and trypsin. Biochim Biophys Acta 1980; 632: 284-289
• 27 Walz A, Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990; 171: 449-454
• 28 Härter L, Peterson F, Flad H-D, Brandt E. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2. J Immunol 1994; 153: 5698-5708
• 29 Yan Z, Holt JC, Stewart GJ, Niewiarowski S. Neutrophil-activating inter-crine secreted by porcine platelets is active without proteolytic processing. Am J Physiol 1993; 265: C1396-C1404
• 30 Rucinski B, Poggi A, James P, Holt JC, Niewiarowski S. Purification of two heparin-binding proteins from porcine platelets and their homology with human secreted platelet proteins. Blood 1983; 61: 1072-1080
• 31 Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691
• 32 van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79: 116-124
• 33 Reilly IAG, Doran JB, Smith B, Fitzgerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300-1309
• 34 Stewart ME, Douglas JT, Lowe GDO, Prentice CRM, Forbes CD. Prognostic value of beta-thromboglobulin in patients with transient cerebral ischae-mia. Lancet 1983; 2: 479-482
• 35 Mehta J, Dinerman J, Mehta P, Saldeen TGP, Lawson D, Donnelly WH, Wallin R. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549-556
• 36 Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, Bramucci E, Angoli L, Marsico F, Specchia G, Notario A. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-363
• 37 Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-236
• 38 Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders?. Am Rev Respir Dis 1987; 135: 482-492
• 39 Morley J, Sanjar S, Page CP. The platelet in asthma. Lancet 1984; 2: 1142-1144
• 40 Johnson RJ, Alpers CE, Pritzl P, Schulze M, Baker P, Pruchno C, Couser WG. Platelets mediate neutrophil-dependent immune complex nephritis in the rat. J Clin Invest 1988; 82: 1225-1235